Measuring function in rheumatoid arthritis - Identifying reversible and irreversible components

被引:242
作者
Aletaha, Daniel
Smolen, Josef
Ward, Michael M.
机构
[1] Med Univ Vienna, Dept Rheumatol, A-1090 Vienna, Austria
[2] NIAMSD, NIH, Bethesda, MD 20892 USA
[3] Hietzing Hosp, Vienna, Austria
来源
ARTHRITIS AND RHEUMATISM | 2006年 / 54卷 / 09期
关键词
D O I
10.1002/art.22052
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Measurement of physical function at one point in time cannot distinguish impairment caused by the active disease process from chronic irreversible impairment. We aimed to dissect these two components of functional limitation in rheumatoid arthritis (RA) by using the disability index of the Health Assessment Questionnaire (HAQ) as the measure of function. Methods. We performed a secondary analysis of data from 6 contemporary clinical trials of RA (2,763 patients). Patients in whom remission was achieved in the trials, based on a simplified disease activity index, were identified. In an individual patient, HAQ scores at trial entry represented both reversible and irreversible impairments, while HAQ scores at the time of RA remission represented the mostly irreversible component, and the difference between these corresponded to the component related to disease activity. We tested the concept that the HAQ has a reversible and an irreversible component by associating the HAQ score during remission with 2 measures associated with the degree of accrued damage: duration of RA and radiographic severity. Results. Among patients in whom clinical remission was achieved (n = 295), average HAQ scores despite clinical remission increased progressively with the duration of RA, from 0.19 (< 2 years of RA) to 0.36 (2-< 5 years) to 0.38 (5-< 10 years) to 0.55 (>= 10 years) (P < 0.001). The reversibility of HAQ scores decreased with the duration of RA (median 100%, 83.3%, 81.9%, and 66.7%, respectively; P < 0.001). Findings were similar in patients subgrouped by quartile of radiographic scores. Conclusion. Differences in the sources of functional limitations should be considered in the interpretation of functional measures, and in their use for prediction and in cost analyses.
引用
收藏
页码:2784 / 2792
页数:9
相关论文
共 37 条
  • [1] Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials
    Aletaha, D
    Ward, MM
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (02) : 227 - 233
  • [2] Aletaha D, 2005, CLIN EXP RHEUMATOL, V23, pS100
  • [3] Remission and active disease in rheumatoid arthritis - Defining criteria for disease activity states
    Aletaha, D
    Ward, MM
    Machold, KP
    Nell, VPK
    Stamm, T
    Smolen, JS
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : 2625 - 2636
  • [4] ALETAHA D, 2006, RHEUMATOLOGY OXFORD
  • [5] Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden
    Bansback, NJ
    Brennan, A
    Ghatnekar, O
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (07) : 995 - 1002
  • [6] Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis
    Breedveld, FC
    Han, C
    Bala, M
    van der Heijde, D
    Baker, D
    Kavanaugh, AF
    Maini, RN
    Lipsky, PE
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (01) : 52 - 55
  • [7] Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK
    Brennan, A
    Bansback, N
    Reynolds, A
    Conway, P
    [J]. RHEUMATOLOGY, 2004, 43 (01) : 62 - 72
  • [8] Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial
    Clair, EWS
    van der Heijde, DMFM
    Smolen, JS
    Maini, RN
    Bathon, JM
    Emery, P
    Keystone, E
    Schiff, M
    Kalden, JR
    Wang, B
    DeWoody, K
    Weiss, R
    Baker, D
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (11): : 3432 - 3443
  • [9] Drossaers-Bakker KW, 1999, ARTHRITIS RHEUM, V42, P1854, DOI 10.1002/1529-0131(199909)42:9<1854::AID-ANR9>3.0.CO
  • [10] 2-F